166 related articles for article (PubMed ID: 31911839)
1. Rituximab utilization for approved and off-label nononcology indications and patients' experiences with the Patient Alert Card.
Sarsour K; Beckley-Kartey S; Melega S; Odueyungbo A; Kirchner P; Khalife N; Bangs J
Pharmacol Res Perspect; 2020 Feb; 8(1):e00555. PubMed ID: 31911839
[TBL] [Abstract][Full Text] [Related]
2. Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event.
Berger JR; Malik V; Lacey S; Brunetta P; Lehane PB
J Neurovirol; 2018 Jun; 24(3):323-331. PubMed ID: 29508305
[TBL] [Abstract][Full Text] [Related]
3. Progressive multifocal leukoencephalopathy in patients treated with rituximab: a 20-year review from the Southern Network on Adverse Reactions.
Bennett CL; Focosi D; Socal MP; Bian JC; Nabhan C; Hrushesky WJ; Bennett AC; Schoen MW; Berger JR; Armitage JO;
Lancet Haematol; 2021 Aug; 8(8):e593-e604. PubMed ID: 34329579
[TBL] [Abstract][Full Text] [Related]
4. Indications for Rituximab Use in an Integrated Health Care Delivery System.
Delate T; Hansen ML; Gutierrez AC; Le KN
J Manag Care Spec Pharm; 2020 Jul; 26(7):832-838. PubMed ID: 32584674
[TBL] [Abstract][Full Text] [Related]
5. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis.
Clifford DB; Ances B; Costello C; Rosen-Schmidt S; Andersson M; Parks D; Perry A; Yerra R; Schmidt R; Alvarez E; Tyler KL
Arch Neurol; 2011 Sep; 68(9):1156-64. PubMed ID: 21555606
[TBL] [Abstract][Full Text] [Related]
6. Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis.
Fleischmann RM
Arthritis Rheum; 2009 Nov; 60(11):3225-8. PubMed ID: 19877057
[TBL] [Abstract][Full Text] [Related]
7. Assessing understanding of individual risk and symptoms of progressive multifocal leukoencephalopathy in patients prescribed natalizumab for multiple sclerosis.
Rath L; Vijiaratnam N; Skibina O
Intern Med J; 2017 Feb; 47(2):194-199. PubMed ID: 27862809
[TBL] [Abstract][Full Text] [Related]
8. Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.
Oshima Y; Tanimoto T; Yuji K; Tojo A
Mult Scler; 2019 Jul; 25(8):1141-1149. PubMed ID: 29985084
[TBL] [Abstract][Full Text] [Related]
9. Rituximab as an effective and probably safe treatment for granulomatosis with polyangiitis (Wegener's Granulomatosis).
Tavakolpour S; Alesaeidi S
Int Immunopharmacol; 2019 May; 70():67-68. PubMed ID: 30785092
[No Abstract] [Full Text] [Related]
10. Drug-induced progressive multifocal leukoencephalopathy: Lessons learned from contrasting natalizumab and rituximab.
Vermeer NS; Straus SM; Mantel-Teeuwisse AK; Hidalgo-Simon A; Egberts AC; Leufkens HG; De Bruin ML
Clin Pharmacol Ther; 2015 Nov; 98(5):542-50. PubMed ID: 26347128
[TBL] [Abstract][Full Text] [Related]
11. Linking process indicators and clinical/safety outcomes to assess the effectiveness of abatacept (ORENCIA) patient alert cards in patients with rheumatoid arthritis.
Artime E; Kahlon R; Méndez I; Kou T; Garrido-Estepa M; Qizilbash N
Pharmacoepidemiol Drug Saf; 2020 Jun; 29(6):664-674. PubMed ID: 32394485
[TBL] [Abstract][Full Text] [Related]
12. Rituximab Biosimilar Prevents Poor Outcomes of Microscopic Polyangiitis and Granulomatosis with Polyangiitis as Effectively as Rituximab Originator.
Kwon HC; Kim MK; Song JJ; Park YB; Lee SW
Yonsei Med J; 2020 Aug; 61(8):712-719. PubMed ID: 32734735
[TBL] [Abstract][Full Text] [Related]
13. [Recommendations on the use of rituximab for ANCA-associated vasculitis].
Gause AM; Rubbert-Roth A;
Z Rheumatol; 2014 Apr; 73(3):287-9. PubMed ID: 27039911
[TBL] [Abstract][Full Text] [Related]
14. Patient Preferences for Rituximab Additional Risk Minimization Measures: Results From an International Online Survey.
Schneiderova K; Bere N; Stenver DI; Straus SMJM
J Patient Saf; 2022 Jun; 18(4):331-336. PubMed ID: 34608891
[TBL] [Abstract][Full Text] [Related]
15. [Psoriatic arthritis during rituximab treatment of granulomatosis with polyangiitis: a new paradoxical side effect?].
Aussy A; Girszyn N; Vandhuick T; Marie I; Vittecoq O; Lévesque H; Benhamou Y
Rev Med Interne; 2015 Jul; 36(7):491-4. PubMed ID: 25554400
[TBL] [Abstract][Full Text] [Related]
16. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.
Carson KR; Evens AM; Richey EA; Habermann TM; Focosi D; Seymour JF; Laubach J; Bawn SD; Gordon LI; Winter JN; Furman RR; Vose JM; Zelenetz AD; Mamtani R; Raisch DW; Dorshimer GW; Rosen ST; Muro K; Gottardi-Littell NR; Talley RL; Sartor O; Green D; Major EO; Bennett CL
Blood; 2009 May; 113(20):4834-40. PubMed ID: 19264918
[TBL] [Abstract][Full Text] [Related]
17. Progressive multifocal leukoencephalopathy and rheumatoid arthritis treatments.
Clavel G; Moulignier A; Semerano L
Joint Bone Spine; 2017 Dec; 84(6):671-675. PubMed ID: 28323224
[TBL] [Abstract][Full Text] [Related]
18. Progressive Multifocal Leukoencephalopathy Following Treatment with Rituximab in an HIV-Negative Patient with Non-Hodgkin Lymphoma. A Case Report and Literature Review.
Felli V; Di Sibio A; Anselmi M; Gennarelli A; Sucapane P; Splendiani A; Catalucci A; Marini C; Gallucci M
Neuroradiol J; 2014 Dec; 27(6):657-64. PubMed ID: 25489887
[TBL] [Abstract][Full Text] [Related]
19. Progressive multifocal leukoencephalopathy (PML) in a patient with lymphoma treated with rituximab: A case report and literature review.
Al-Tawfiq JA; Banda RW; Daabil RA; Dawamneh MF
J Infect Public Health; 2015; 8(5):493-7. PubMed ID: 25666327
[TBL] [Abstract][Full Text] [Related]
20. Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological immunomodulating agents.
Piccinni C; Sacripanti C; Poluzzi E; Motola D; Magro L; Moretti U; Conforti A; Montanaro N
Eur J Clin Pharmacol; 2010 Feb; 66(2):199-206. PubMed ID: 19838692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
